Latanoprost/Timolol Arrow (Timolol Maleate, Latanoprost)

• Latanoprost/Timolol Arrow is used in the management of ocular conditions characterized by elevated intra‑ocular pressure.
• Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
• Ocular hypertension: lowers pressure to prevent conversion to glaucoma.
• Secondary open‑angle glaucoma: provides combined pressure‑lowering action when monotherapy is insufficient.

• Latanoprost binds to prostaglandin F‑type receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor, while timolol maleate non‑selectively blocks beta‑adrenergic receptors in the ciliary epithelium, decreasing aqueous humor production. The dual action results in a net reduction of intra‑ocular pressure.

Latanoprost/Timolol Arrow may cause ocular and systemic adverse reactions.

Common Side Effects

• Eye irritation or burning sensation
• Transient blurred vision
• Conjunctival hyperemia (redness)
• Increased eyelash length or density
• Darkening of the iris or peri‑ocular skin
• Mild headache

Serious or Rare Side Effects

• Severe allergic reaction (angio‑edema, anaphylaxis)
• Worsening of glaucoma or sudden loss of vision
• Chest pain or myocardial ischemia
• Bradycardia or marked hypotension
• Persistent eye pain or ulceration
• Acute anterior uveitis

• Before prescribing Latanoprost/Timolol Arrow, clinicians should consider several safety aspects.
• Assess baseline intra‑ocular pressure: ensure appropriate monitoring after initiation.
• Screen for asthma or chronic obstructive pulmonary disease: beta‑blocker component may exacerbate bronchospasm.
• Monitor heart rate and blood pressure: timolol can cause bradycardia or hypotension.
• Avoid use in patients with known sulfonamide allergy: timolol maleate contains a sulfonamide moiety.
• Do not combine with other prostaglandin analog eye drops: risk of additive ocular effects.
• Store at room temperature: keep bottle tightly capped, protect from light and freezing.

Latanoprost/Timolol Arrow can interact with systemic and ocular medications.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers (e.g., propranolol): additive bradycardia/hypotension.
• Other intra‑ocular pressure‑lowering agents (e.g., carbonic anhydrase inhibitors): risk of excessive pressure reduction.
• Sympathomimetic agents (e.g., epinephrine eye drops): may diminish timolol efficacy.

Moderate Interactions (Monitor Closely)

• Anticholinergic eye drops: possible reduced ocular absorption.
• CYP2D6 inhibitors (e.g., fluoxetine): may increase timolol plasma levels.
• NSAIDs used topically: potential for corneal irritation when combined.